<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13405">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02932410</url>
  </required_header>
  <id_info>
    <org_study_id>AC-055-312</org_study_id>
    <nct_id>NCT02932410</nct_id>
  </id_info>
  <brief_title>A Study to Find Out Whether the Medicine Macitentan Works in Children With Pulmonary Arterial Hypertension (PAH)</brief_title>
  <acronym>TOMORROW</acronym>
  <official_title>TOMORROW: pediaTric Use Of Macitentan tO Delay Disease pRogRessiOn in PAH Worldwide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actelion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicenter, open-label, randomized, controlled, parallel group,
      group-sequential, event-driven Phase 3 study to evaluate efficacy, safety and PK of
      macitentan in children.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 30, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to the first CEC-confirmed disease progression event</measure>
    <time_frame>Between randomization and EOS/study closure; up to 6 years</time_frame>
    <description>Time to the first of the following CEC-confirmed disease progression events: • Death (all causes) • Atrial septostomy or Potts' anastomosis, or registration on lung transplant list • Hospitalization due to worsening PAH • Clinical worsening of PAH</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first CEC-confirmed hospitalization for PAH occurring between randomization and EOS</measure>
    <time_frame>Between randomization and EOS/study closure; up to 6 years</time_frame>
    <description>Time to first CEC-confirmed hospitalization for PAH occurring between randomization and EOS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to CEC-confirmed death due to PAH occurring between randomization and EOS</measure>
    <time_frame>Between randomization and EOS/study closure; up to 6 years</time_frame>
    <description>Time to CEC-confirmed death due to PAH occurring between randomization and EOS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death (all causes) occurring between randomization and Study Closure</measure>
    <time_frame>Between randomization and EOS/study closure; up to 6 years</time_frame>
    <description>Time to death (all causes) occurring between randomization and Study Closure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Macitentan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACT-064992</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard-of-care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard-of-care as per site's clinical practice which may comprise treatment with PAH non-specific treatment and/or up to two PAH-specific medications excluding macitentan and i.v./s.c. prostanoids.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Macitentan</intervention_name>
    <description>Dispersible tablet; Oral use</description>
    <arm_group_label>Macitentan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard-of-care</intervention_name>
    <description>Standard-of-care as per site's clinical practice which may comprise treatment with PAH non-specific treatment and/or up to two PAH-specific medications excluding macitentan and i.v./s.c. prostanoids.</description>
    <arm_group_label>Standard-of-care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent by the parent(s) or legally designated representative AND
             assent from developmentally capable children prior to initiation of any
             study-mandated procedure.

          2. Males or females between ≥ 2 years and &lt; 18 years of age.

          3. Subjects with body weight ≥ 10 kg at randomization.

          4. PAH diagnosis, confirmed by historical RHC (mPAP ≥ 25 mmHg, and PAWP ≤ 15 mmHg, and
             PVR &gt; 3 WU).

          5. PAH belonging to the Nice 2013 Updated Classification Group 1 (including subjects
             with Down syndrome) and of following etiologies:

               -  iPAH

               -  hPAH

               -  PAH associated with CHD

               -  Drug or toxin induced PAH

               -  PAH associated with HIV

               -  PAH-aCTD

          6. WHO FC I to III.

          7. Females of childbearing potential must have a negative pregnancy test at Screening
             and at Baseline, and must agree to undertake monthly pregnancy tests, and to use a
             reliable method of contraception (if sexually active) up to EOS.

        Exclusion Criteria:

          1. Subjects with PAH due to portal hypertension, schistosomiasis, or with pulmonary
             veno-occlusive disease and/or pulmonary capillary hemangiomatosis, and persistent
             pulmonary hypertension of the newborn.

          2. Subjects receiving a combination of &gt; 2 PAH-specific treatments at randomization.

          3. Treatment with i.v. or s.c. prostanoids within 4 weeks before randomization, unless
             given for vasoreactivity testing.

          4. Hemoglobin or hematocrit &lt;75% of the lower limit of normal range

          5. Serum AST and/or ALT &gt; 3 times the upper limit of normal range'

          6. Pregnancy (including family planning) or breastfeeding.

          7. Any circumstances or conditions, which, in the opinion of the investigator, may
             affect full participation in the study or compliance with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>CTD clinical trial disclosure desk</last_name>
    <email>clinical-trials-disclsure@actelion.com</email>
  </overall_contact>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 17, 2017</lastchanged_date>
  <firstreceived_date>October 12, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Macitentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
